Document:

First Amendment to License Agreement

 Exhibit 10.83 
 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO
RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

FIRST AMENDMENT TO LICENSE AGREEMENT 
 This Amendment to License Agreement (“Amendment”) is made effective as of May 19. 2005 (the “Effective Date”) by and between Japan Tobacco Inc., a Japanese
corporation having a principal place of business at JT Bldg. 2-1, Toranomon 2-chome, Minato-ku, Tokyo 105-8422, Japan (hereinafter, “JT”), and Gilead Sciences, Inc., a corporation having a principal place business at 333 Lakeside Drive,
Foster City, California, U.S.A. (hereinafter, “GILEAD”). 
 RECITALS 

WHEREAS, JT and GILEAD have previously entered into a License Agreement dated March 22, 2005 relating to JTK-303 (the
“Agreement”). 
 WHEREAS, JT and GILEAD desire to amend certain terms of the Agreement 

NOW THEREFORE, based on the foregoing premises and the mutual covenants and obligations set forth below, the parties agree as follows:

 1.     Amendments 

A.     Section 6.4(a)     Section 6.4(a) of the Agreement
shall be amended and restated as follows: 
 “In the event that either Party obtains from a Third Party a
license to Patents, Know-How and/or a trademark that is necessary for, or actually used during the Term in, the Party’s Development or Commercialization of a Product, such Party shall, subject to Section 6.4(b), use its commercially
reasonable efforts to include in such license aright to grant a sublicense on the same terms and conditions to the other Party solely to support the license grants contained in Sections 6.1 and 6.2.” 

B.     Section 16.1     Section 16.1 of the Agreement
shall be amended and restated as follows: 
 “16,1.       Entire
Agreement; Amendment. 

 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED 
  

(a)       This Agreement, including the Schedules attached hereto and incorporated herein,
sets forth the complete, final and exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties with respect to the subject matter hereof and supersedes and
terminates all prior agreements and understandings between the Parties, except for the Confidential Disclosure Agreements and Material Transfer Agreements with respect to such subject matter, as amended pursuant to Section 16.1(b) hereof.

 (b)       The Confidential Disclosure Agreements (other than the Confidential
Disclosure Agreement dated February 1, 2005 (Gilead as recipient with respect to JTK-403)) and the Material Transfer Agreements are hereby considered amended to the extent necessary to provide that, notwithstanding any provision in such
agreements to the contrary, any information and materials provided by one Party to the other Party pursuant to the Confidential Disclosure Agreements or the Material Transfer Agreements may be used by a Party to fulfill any obligation or to pursue
any rights such Party has under this Agreement, including without limitation for the Development of Products. 

(c)       Except for the Confidential Disclosure Agreements and Material Transfer
Agreements, there are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties with respect to the subject matter hereof other than as are set forth in this Agreement.
No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party.” 

C.     Section 16.6     Section 16.6 of the Agreement
shall be amended and restated as follows: 
 “Neither Party may assign or transfer this
Agreement or any rights or obligations hereunder without the prior written consent of the other Party, except that, subject to Section 16.7, a Party may make such an assignment or transfer without the other Party’s consent to the assigning
Party’s Affiliates or to its successor to all or substantially all of the business of such Party in the field to which this Agreement relates (whether by merger, sale of stock, sale of assets or other transaction), provided that any such
successor (other than an Affiliate) shall, in a writing reasonably acceptable to the other Party, expressly assume performance of such rights or obligations. The JT Technology and the Gilead Technology shall exclude any intellectual property held or
developed by such a successor of the relevant Party not in connection with Compound or Products. Any such assignment shall be binding on the successors of the assigning Party. Any assignment or attempted assignment by either Party in violation of
the terms of this Section 16.6 shall be null and void.” 

 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED 
  

2.     The Parties have each designated the three representatives to serve on the Joint Committee, one
representative to serve as Alliance Manager and the three representatives to serve on the IP subcommittee, respectively, named on Schedule 2.2, Schedule 2.3 and Schedule 9.2, attached hereto. 

3.     Defined Terms 
 Unless otherwise defined herein, all of the capitalized terms used in this Amendment shall have the respective meanings ascribed to them in the Agreement 

4.     Effect 
 Except as expressly amended by this Amendment, the Agreement remains in full force and effect. 
 5.     Governing Law 
 This Amendment shall be governed
and construed in accordance with the substantive laws of the State of New York and the federal law of the United States of America. 
 IN WITNESS WHEREOF, the parties have caused this Amendment to be executed by their duly authorized representatives as of the Effective Date. 

 

									
	JAPAN TOBACCO INC.	 		 	GILEAD SCIENCES, INC.
					
	BY:	 	/s/ Noriaki Okubo	 		 	BY:	 	/s/ John F. Millingan
			
	 NAME: Noriaki Okubo
	 		 	NAME: John F. Milligan, Ph.D.
			
	 TITLE: President, Pharmaceutical Business
	 		 	 TITLE: Executive Vice President & CFO

 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED 
  

SCHEDULE 2.2 
 Members of the Joint Committee 
 Gilead: 

[*] 
 [*] 

[*] 
 JT: 

[*] 
 [*] 

[*] 

 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED 
  

SCHEDULE 2.3 
 Alliance Managers 
 Gilead: 
 [*] 
 JT: 
 [*] 

 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED 
  

SCHEDULE 9.2 
 IP subcommittee members 
 Gilead: 

[*] 
 [*] 

[*] 
 JT: 

[*] 
 [*] 

[*]Second Amendment to License Agreement

			
	 Execution Copy
	 	Exhibit 10.84

 SECOND AMENDMENT TO LICENSE AGREEMENT 

THIS SECOND AMENDMENT (the “Amendment”) is made and entered into as of May 17, 2010 (the “Amendment
Execution Date”) by and between JAPAN TOBACCO INC., a Japanese corporation having its principal place of business at JT Building, 2-1 Toranomon, 2-chome, Minato-ku, Tokyo 105-8422, Japan (“JT”), and GILEAD SCIENCES,
INC., a Delaware corporation having its principal place of business at 333 Lakeside Drive, Foster City, CA 94404, United States (“Gilead”). JT and Gilead are sometimes referred to herein individually as a “Party” and
collectively as the “Parties.” 
 RECITALS 

WHEREAS, JT and Gilead have previously entered into a License Agreement dated March 22, 2005 which was amended on
May 19, 2005 (such License Agreement, as amended previously and contemporaneously with this Amendment, the “EVG Agreement”) relating to a compound designated as JTK-303, which is now known as Elvitegravir (“EVG”);

 WHEREAS, Gilead is developing a combination product containing EVG and known as the “Quad,” as defined
below; 
 WHEREAS, Gilead and JT have previously entered into a Supply Agreement dated December 25, 2003 (as
amended previously and contemporaneously with this Amendment, the “Supply Agreement”) for the supply by Gilead to JT of certain products; and 
 WHEREAS, JT and Gilead have previously entered into a License Agreement dated July 31, 2003 (such License Agreement, as amended previously and contemporaneously with this Amendment, the “VTE
License”) relating to the development and commercialization of FTC, TDF and Truvada in the JT Territory. 
 NOW THEREFORE,
based on the foregoing premises and the mutual covenants and obligations set forth below, the Parties agree as follows: 
 ARTICLE 1

 DEFINITIONS 
 Unless otherwise specified, capitalized terms not defined in this Amendment shall have the definitions set forth therefor in the EVG Agreement. The EVG Agreement is hereby amended by adding the following defined
terms: 
 1.1       “Component” shall mean an API component
of the Quad, namely, FTC, TDF, EVG or GS-9350. 
 1.2      
“FBC” shall mean Fully Burdened Cost as defined in the Supply Agreement. 

1.3       “FBCFP” shall mean Gilead’s FBC to manufacture the
Quad formulated product (as delivered to JT pursuant to the Supply Agreement, for example, brite stock) from the TDF, FTC, GS-9350 and EVG APIs. 

  
 -1- 

 [*] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED 

 Execution Copy 
  
 1.4       “FTC” shall mean an enantiomeric
mixture of emtricitabine (which is the (-) enantiomer of the chemical (2R-cis)-4-amino-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone), in which the ratio of such (-) enantiomer to its (+) enantiomer is equal to or
greater than ninety (90) to ten (10), including without limitation the ratio of such enantiomers being one hundred (100) to zero (0). 
 1.5       “GS-9350” shall mean thiazol-5-ylmethyl
(2R,5R)-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-4-morpholinobutanamido)-1,6-diphenylhexan-2-ylcarbamate. 
 1.6       [*]. 

1.7       “Listed Price” shall mean the drug price listed on the
National Health Insurance price list issued by the Japan Ministry for Health Labor and Welfare, or any successor thereto, for Japanese health insurance reimbursement purposes. 

1.8       “Net Sales” shall mean Net Sales as defined in
Section 1.46 of the VTE License. 
 1.9       “Quad”
shall mean a combination pharmaceutical product in oral formulation as developed by Gilead containing as its sole APIs FTC, TDF, EVG and GS-9350. 

1.10     “TDF” shall mean tenofovir disoproxil fumarate, having the chemical
formula (9-[(R)-2-[[bis [[isopropoxycarbonyl)oxy] methoxy] phosphinyl] methoxy] propyl] adenine fumarate). 
 1.11     “Truvada” shall mean the combination product sold in the JT Territory under the VTE License by JT containing both TDF and FTC as its sole APIs. 

1.12     “Truvada Share” shall have the meaning set forth in Section 2.3
below. 
 1.13     “TVD Component” shall mean the TDF and FTC
Components of the Quad. 
 ARTICLE 2 
 QUAD 
 2.1       Relationship
to EVG License. The Parties agree that the Quad is a “Product” under the EVG Agreement and therefore the rights and obligations of the Parties with respect to the development and commercialization of the Quad in the JT Territory shall
be as set forth in the EVG Agreement. The Parties further agree that with respect to the Quad, the last sentence of the definition of “Know-How” in Section 1.56 of the EVG Agreement shall not apply to the Quad. The definitions of
“Gilead Know-How,” “JT Know-How,” and “Sublicensee Know-How” therefore shall, with respect to the Quad, be construed without application of the last sentence of Section 1.56 of the EVG Agreement. 

  
 -2- 

 [*] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED 

 Execution Copy 
  
 2.2       Supply of Quad. JT shall obtain its supply
of the Quad for development and commercial purposes from Gilead and Gilead shall provide such supply, as set forth in an amendment to the Supply Agreement entered into with the same effective date as this Amendment. JT agrees that the Quad obtained
under the Supply Agreement shall be sold only in the JT Territory. 

2.3       Transfer Price for Quad. JT shall pay Gilead a transfer price for
the Quad supplied by Gilead in accordance with the Supply Agreement. The transfer price for the Quad supplied for clinical trial use or development purposes shall be [*] for such supply. The transfer price for commercial supply of the Quad
shall be the sum of the [*]. The transfer price for the EVG Component and the GS-9350 Component shall be [*]. The transfer price for the TVD Component shall be calculated using the following formula: 

[*] 
 For clarification, the transfer price of the Quad shall not include [*]. 
 In
the event that the [*]. 
 2.4       Transfer Price Change if JT
Manufactures Quad from Gilead API. If JT manufactures the Quad finished product from API supplied by Gilead, then the transfer price JT shall owe for such API shall be reduced as follows: 

The [*] and 
 If JT manufactures some of the Component APIs in the Quad, then [*] for any Component API manufactured by JT for the units manufactured and sold by JT, shall be deducted from the Transfer Price owed by JT.

 For purposes of this Section 2.4 and Section 2.5, Gilead’s FBCFP and (if applicable) API FBC shall be
determined as set forth in the Supply Agreement based on data used to compute the average per-unit FBC for the full calendar year preceding the transfer of manufacturing to JT. Gilead shall calculate such FBCFP and FBC and provide the resulting
calculations to JT; such calculations to be subject to JT’s approval which shall not be unreasonably withheld. 
 2.5       Royalty if JT Manufactures Quad. If JT manufactures the Quad (including all its APIs), then JT shall pay Gilead a royalty on sales of the Quad manufactured by JT and
sold in the JT Territory calculated using the following formula: 
 Royalty = [*] 

JT shall pay such royalty to Gilead for each calendar quarter within forty-five (45) days after the end of such calendar
quarter. JT shall provide quarterly royalty reports as set forth in the first sentence of Section 8.6(a) of the VTE License (taking into consideration that JT will not be paying estimated transfer prices if Gilead does not manufacture the Quad
for JT) and shall provide the additional information set forth in Section 8.6(b), with respect to the Quad manufactured by JT. The provisions of Sections 8.7 through 8.12 of the VTE License shall apply to such royalty payments, as appropriate.
For purposes of this Section 2.5, the FBC of the Quad shall be [*] determined as set forth in the Supply 

  
 -3- 

 [*] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED 

 Execution Copy 
  
 
Agreement based on data used to compute the [*] for the full calendar year preceding the transfer of manufacturing to JT. Gilead shall calculate such FBC and provide the resulting
calculations to JT; such calculations to be subject to JT’s approval which shall not be unreasonably withheld. 

EXAMPLE: 
 JT (or its contract manufacturer) manufactures TDF and FTC APIs and manufactures the Quad from these APIs and from GS-9350 API and EVG API manufactured by Gilead. Gilead’s FBCFP is $5/unit and its FBC to
manufacture TDF and FTC API is $20/unit. For the Quad units JT manufactures and sells, it will owe [*] 
 2.6       Net Sales Calculation and Transfer Price Payments. JT shall calculate Net Sales of the Quad using the methodologies and definitions in the VTE License, and not the
methodologies and definitions therefor in the EVG Agreement. The provisions of Sections 8.6 through 8.12 of the VTE License shall apply to JT’s transfer price payments set forth in this Amendment. 

2.7       [*] 

2.8       [*] payments. [*] 

2.9       Information Exchange / Regulatory Data. Gilead shall, upon
reasonable request of JT, make available to JT as soon as practicable after such request, Gilead Know-How and Regulatory Information with respect to (i) the Quad, (ii) GS-9350 as a Component, and (iii) GS-9350 as a single agent or
stand-alone product, which is Controlled by Gilead, and Gilead’s Affiliates or Sublicensees as a result of the performance of Gilead’s obligations under the EVG Agreement. For the avoidance of doubt, Regulatory Information about GS-9350 as
a single agent or stand-alone product shall include that about combination use and drug-drug interactions of such GS-9350 single agent with other agents, provided that Gilead agrees that such information is required for Regulatory Approval of the
Quad for the Licensed Indication in the JT Territory (such agreement not to be unreasonably withheld or delayed). 
 If
the Regulatory Authority in the JT Territory request any material information, data (in final report form) or Know-How that is included in the Marketing Authorization Applications and INDs for the Quad or GS-9350 (including any combination products
containing GS-9350) filed by Gilead or its Affiliates or licensees anywhere in the world for any indications (including those outside the Licensed Indication), and JT reasonably determines that the provision of such material information, data (in
final report form) or Know-How is required for Regulatory Approval of the Quad for the Licensed Indication in the JT Territory, then JT shall notify Gilead in writing of such determination. If Gilead agrees with JT’s determination (such
agreement not to be unreasonably withheld or delayed), then Gilead shall provide JT with such additional material information, data (in final report form) and Know-How (subject to Gilead’s obligations under its agreements with Third Parties),
together with all material subsequent correspondence and data submissions relating to the foregoing, as soon as practicable. If Gilead does not agree with JT’s determination, then Gilead shall have no obligation to provide JT with such
additional material information, 

  
 -4- 

 [*] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED 

 Execution Copy 
  
 
data (in final report form) or Know-How if Gilead has not unreasonably withheld the needed agreement as provided in the prior sentence. 

2.10     Exception for Termination. In case (i) that the EVG Agreement expires
pursuant to Section 14.1 of the EVG Agreement or that Gilead terminates the EVG Agreement pursuant to Section 14.2 thereof for any reasons other than significant safety reasons with respect to GS-9350 and (ii) that EVG is approved
either in the United States of America or the EU at that time and is not withdrawn from the market, if JT notifies Gilead that it wishes to continue to Develop and/or Commercialize the Quad in the JT Territory, the EVG Agreement shall be deemed to
be still valid in the JT Territory with regard to the Quad as a Product under the EVG Agreement until [*] Upon the expiration of said term with respect to Development and/or Commercialization of the Quad in the JT Territory, if requested by
JT, the Parties shall discuss in good faith extension or renewal of such term. 
 ARTICLE 3 

MODIFICATIONS 
 3.1       Survival. With respect to the Product in the JT Territory, Sections 6.2 and 6.3 shall survive any termination or expiration of the EVG Agreement pursuant to
Section 14.1 or 14.2 or termination by JT pursuant to Section 14.3 or 14.4; provided that if Gilead requests and if permitted by Regulatory Authority in the JT Territory, JT shall cease using “GILEAD” and other versions of
Gilead’s corporate name or logo in connection with the marketing of the Product in the JT Territory. 
 ARTICLE 4 

MISCELLANEOUS 
 4.1       Effect. Except as expressly amended by this Amendment, the EVG Agreement remains in full force and effect. 

4.2       Governing Law. This Amendment shall be governed and construed in
accordance with the substantive laws of the State of New York and the federal law of the United States of America without regard to its conflict of law rules that would require the application of the laws of a foreign state or country. 

4.3       Entire Agreement; Amendment. This Amendment together with the EVG
Agreement, Supply Agreement and the sections of the VTE License referred to herein, set forth the complete, final and exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings between
the Parties with respect to the subject matter hereof and supersedes and terminates all prior agreements and understandings between the Parties. There are no covenants, promises, agreements, warranties, representations, conditions or understandings,
either oral or written, between the Parties other than as are set forth in this Amendment. No subsequent alteration, amendment, change or addition to this Amendment shall be binding upon the Parties unless reduced to writing and signed by an
authorized officer of each Party. 

  
 -5- 

 [*] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED 

 Execution Copy 
  
 4.4       Further Actions. Each Party agrees to
execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Amendment. 

4.5       Headings. The headings for each Article and Section in this
Amendment have been inserted for convenience of reference only and are not intended to limit or expand on the meaning of the language contained in the particular Article or Section. 

4.6       Translations. This Amendment is in the English language only, which
language shall be controlling in all respects, and all versions hereof in any other language shall be for accommodation only and shall not be binding upon the Parties. All communications and notices to be made or given pursuant to this Amendment,
and any dispute proceeding related to or arising hereunder, shall be in the English language. If there is a discrepancy between any Japanese translation of this Amendment and this Amendment, this Amendment shall prevail. 

4.7       Counterparts. This Amendment may be executed in two (2) or more
counterparts, each of which shall be deemed an original, but all of which together shall constitute one (1) and the same instrument. 
 4.8       Change of the Mailing Address. The mailing addresses of JT set forth in Section 16.3 of the EVG Agreement shall be replaced with the following: 

 

	 	 For JT:
	     Japan Tobacco Inc. 

	 	     
	     Pharmaceutical Division 

	 	     
	     JT Building, 2-1 Toranomon, 2-chome 

	 	     
	     Minato-ku, Tokyo 105-8422, Japan 

	 	     
	     Attention: Vice President, Business Development 

	 	     
	     Facsimile: [*] 

	 	 With a copy to:    
	 Holland & Knight LLP 

	 	     
	     31 West 52nd Street 

	 	     
	     New York NY 10019 USA 

	 	     
	     Attn: Neal Beaton, Esq. 

	 	     
	     Fax: 1-212-341-7103 

 IN WITNESS WHEREOF the Parties have executed this Amendment in duplicate originals by their duly authorized officers as of the Amendment Execution Date. 

 

									
	 Gilead Sciences, Inc.
	 		 	 Japan Tobacco Inc.

					
	 By:
	 	   /s/ John F. Milligan
                                        

	 		 	 By:
	 	   /s/ Noriaki
Okubo                                        
            

	         Name: John F. Milligan, Ph.D.
	 		 	         Name: Noriaki Okubo

	 Title: President & Chief Operating Officer
	 		 	 Title: President, Pharmaceutical Business

	 Date: August 30,
2011                                       
             
	 		 	 Date: August 30,
2011                                         
           

  
 -6- 

 [*] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}]]